{"name":"Venus Medtech","slug":"venus-medtech","ticker":"2500","exchange":"HKEX","domain":"venusmedtech.com","description":"Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the t","hq":"Hangzhou, China","founded":0,"employees":"560","ceo":"Zhongjie Min","sector":"Medical Devices — Structural Heart","stockPrice":1.59,"stockChange":-0.02,"stockChangePercent":-1.24,"marketCap":"$103M","metrics":{"revenue":45214661.33311168,"revenueGrowth":-50.2,"grossMargin":69,"rdSpend":0,"netIncome":-60086514.77755584,"cash":38874594.709359996,"dividendYield":0,"peRatio":21.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Venus Heart Valve patent cliff ($100M at risk)","drug":"Venus Heart Valve","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Venus Medtech Reports Strong Q4 2023 Earnings","summary":"The company reported a 25% increase in revenue and a 30% increase in net income compared to the same period last year.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"deal","headline":"Venus Medtech Partners with Leading Hospital Group","summary":"The partnership aims to expand the company's product offerings and improve patient access to structural heart treatments.","drugName":"","sentiment":"neutral"},{"date":"2022-09-01","type":"regulatory","headline":"Venus Medtech Receives FDA Clearance for New Heart Valve","summary":"The company received FDA clearance for its new transcatheter heart valve, expanding its product portfolio in the US market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNb2twamwwd3piUFdJckF4bG5pZGNFTk9tcGdTUUtJVjNmd3hMVjROTVpEUWhYWWZIMnNUVUF0M3Q0Z2pZRDgzYjRNd3JFMHhhVDdjb2lZem4tRG9VcUVhYUZkeDROSE9Cb3lZeDNvQXdLbFA5MEZzVW5ZSzRFanVkSGwwVDNNSkJaOFRKN0lZSi0yUzBEaHlaaThnZXR5QUFjb1ZiTzV1ZWxKa2VUZUMwNmNFSS1LeTFHdUpMX3M5ci1lVjdrMmk5b0lBSnZCMnJjQzN0XzhTWXF4NjlESHRV?oc=5","date":"2025-10-27","type":"trial","source":"BioPharma APAC","summary":"Venus Medtech Completes Patient Enrollment in Cardiovalve TARGET Study for Tricuspid Valve Replacement - BioPharma APAC","headline":"Venus Medtech Completes Patient Enrollment in Cardiovalve TARGET Study for Tricuspid Valve Replacement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPQU9DTmhJVnJkWlZqTzRIUGc5UmhSSDFPNndQWXlmZlBjYTF6aUp1NldydGxKSkhQbmVudlo2NWFEbkVYYXFqX2xMcE5QcEJZalU4QnVJUzVVbHRjN3B4MkVzcXBIVDBOVFRGVzkxbFJHVnJGdlozb1FZMUxTdXRxMG1NekNCMmxOcWhJRGtDZnhnbWVRMnhLT2xlOWRtcS1iY1NVbDNsMnl6eU5kS3FxcXJBdzFOU3FOcGhGMTJQSHd0UjloUl94Nw?oc=5","date":"2022-01-25","type":"pipeline","source":"PR Newswire","summary":"Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve - PR Newswire","headline":"Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQMHR6V3h3OXFFYXZfSUxIZFh1amd1dFlHckxxUlQwem8ydk9EenVlVDUweTNYQ2lUYzJZRTY2ZWMxc29MNnZRdjV6a2VNVkoySFZoN2hCd01vclA2RHZRbDctUEJGRHhLYVN3YjA4Tm0ydHJucnJicVl5UDZCWm01ZG45MnRGVDBVbnlYTFVXZ01FcUJ5d3E1eXdKZFBZMmdFMUFXSWFBZzNzNmFCVnpiVVF4bXNNTU0?oc=5","date":"2021-04-14","type":"pipeline","source":"The Standard (HK)","summary":"Qiming's Duane Kuang, Nisa Leung named on 2021 Forbes Midas List - The Standard (HK)","headline":"Qiming's Duane Kuang, Nisa Leung named on 2021 Forbes Midas List - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPdFVSWXhMTGtnSkxsWDZ5cHNtSW4yQ0htZG9jLUxFQV8wNDg5Mmlxa1V2a2p4T3dOUmZvVGpkYlpGSGhXdVhRdTUtZm05U3VzdHcxWGc2SmVTUW0wWDJGR2xRaVFKQ2ZuZHRtelZYbUhTSTludU4xbWlabGVkcmlYQV9KWF9KZnF6ZHRiYno2RXV1ZC1IaDJnNUNkVHVVTm9VQXJVdnQwNk5hVGhQd1JfeEdTODFrV2ZoU1lFZ09DZ05xMGFBUmtrSDIyYmE2VnBRanBWeDkwV3NxM1JNY1l4cDROTXBydw?oc=5","date":"2020-07-14","type":"deal","source":"PR Newswire","summary":"Venus Medtech to Partner with Pi-Cardia to Bring its Leaflex(TM) Aortic Valve Technology to China - PR Newswire","headline":"Venus Medtech to Partner with Pi-Cardia to Bring its Leaflex(TM) Aortic Valve Technology to China","sentiment":"neutral"}],"patents":[{"drugName":"Venus Heart Valve","drugSlug":"transcatheter-heart-valve","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Medtronic","Boston Scientific","Abbott Laboratories"],"therapeuticFocus":["Structural Heart","Cardiovascular"],"financials":{"source":"yahoo_finance","revenue":45214663.69122,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":45214663.69122},{"period":"2024-12-31","value":69392200.91441},{"period":"2023-12-31","value":72419422.47021},{"period":"2022-12-31","value":59904941.61597}],"grossProfit":31220175.10264,"grossProfitHistory":[{"period":"2025-12-31","value":31220175.10264},{"period":"2024-12-31","value":54199056.39042},{"period":"2023-12-31","value":57361721.792849995},{"period":"2022-12-31","value":46277581.01646}],"rdSpend":39410474.82508,"rdSpendHistory":[{"period":"2025-12-31","value":39410474.82508},{"period":"2024-12-31","value":50284449.19745},{"period":"2023-12-31","value":77362901.79955},{"period":"2022-12-31","value":77736661.96827}],"sgaSpend":43071437.99188,"operatingIncome":-48251022.91676,"operatingIncomeHistory":[{"period":"2025-12-31","value":-48251022.91676},{"period":"2024-12-31","value":-51082079.33669},{"period":"2023-12-31","value":-84166633.82982999},{"period":"2022-12-31","value":-93570475.04645}],"netIncome":-60086515.95661,"netIncomeHistory":[{"period":"2025-12-31","value":-60086515.95661},{"period":"2024-12-31","value":-105275829.98339},{"period":"2023-12-31","value":-103720510.16458},{"period":"2022-12-31","value":-155885550.74723}],"eps":-0.93,"epsHistory":[{"period":"2025-12-31","value":-0.93},{"period":"2024-12-31","value":-1.63},{"period":"2023-12-31","value":-1.65},{"period":"2022-12-31","value":-2.42}],"cash":23335839.93472,"cashHistory":[{"period":"2025-12-31","value":23335839.93472},{"period":"2024-12-31","value":43925073.203719996},{"period":"2023-12-31","value":114131853.16092},{"period":"2022-12-31","value":276993867.37286997}],"totalAssets":371327190.46084,"totalLiabilities":111540586.88078,"totalDebt":9156534.60656,"equity":259786603.58006,"operatingCashflow":-47360542.26242,"operatingCashflowHistory":[{"period":"2025-12-31","value":-47360542.26242},{"period":"2024-12-31","value":3498695.8380299998},{"period":"2023-12-31","value":-89905679.95363},{"period":"2022-12-31","value":-107508958.56243}],"capex":-1587154.28113,"capexHistory":[{"period":"2025-12-31","value":-1587154.28113},{"period":"2024-12-31","value":-6124596.83412},{"period":"2023-12-31","value":-38747846.387159996},{"period":"2022-12-31","value":-26348028.54998}],"freeCashflow":-48947696.54355,"dividendsPaid":null,"buybacks":0,"employees":560,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.59,"previousClose":1.61,"fiftyTwoWeekHigh":5.47,"fiftyTwoWeekLow":1.53,"fiftyTwoWeekRange":"1.53 - 5.47","fiftyDayAverage":2.04,"twoHundredDayAverage":2.81,"beta":1.22,"enterpriseValue":96916318.3031776,"forwardPE":21.6,"priceToBook":0.34,"priceToSales":2.29,"enterpriseToRevenue":2.14,"enterpriseToEbitda":-2.08,"pegRatio":0,"ebitda":-46487601.21776416,"ebitdaMargin":-102.8,"freeCashflow":0,"operatingCashflow":0,"totalDebt":31884572.121799998,"debtToEquity":12.3,"currentRatio":2.77,"returnOnAssets":-7.5,"returnOnEquity":-20.5,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":4.54,"targetHighPrice":4.54,"targetLowPrice":4.54,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":17,"institutionHeldPercent":18.8,"sharesOutstanding":441010235,"floatShares":289564063,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-1.07,"epsForward":0.07,"revenuePerShare":0.7,"bookValue":4.64,"officers":[{"age":50,"name":"Mr. Hou-Sen  Lim MEng.","title":"GM & Executive Director"},{"age":49,"name":"Ms. Meirong  Liu","title":"VP, Chief Operation Officer & Executive Director"},{"age":40,"name":"Mr. Liqiao  Ma","title":"Executive Director"},{"age":49,"name":"Mr. Renzheng  Ma","title":"VP & Chief Technology Officer"},{"age":null,"name":"Joyce  Heo","title":"Director of Sales"},{"age":63,"name":"Mr. Christopher Lee Richardson","title":"Head of U.S. Operations"},{"age":null,"name":"Mr. Amir  Gross","title":"Head of Venus Global Heart Valve Innovation Center"},{"age":null,"name":"Shakeel  Osman","title":"Head of International Congenital Heart Disease Business"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.venusmedtech.com","phone":"86 571 8777 2180"}}